Cell Source, Inc.
CLCS
Other OTC0.80
USD
-0.06
- -
Cell Source, Inc.
CLCS
(Other OTC)
Recent
price
0.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Cell Source, Inc. (CLCS) is a biotechnology company that develops cell therapy treatments based on immune tolerance management through its proprietary Veto Cell technology; this platform enables selective blocking of immune responses to facilitate safer allogeneic stem cell transplantation, organ transplants, and cancer therapies including Veto CAR-T cells for leukemia, lymphoma, and multiple myeloma; additional applications target non-malignant diseases such as type-1 diabetes, sickle-cell anemia, and multiple sclerosis via bone marrow transplantation with Veto Cells. The company, founded in 2011 and headquartered at 57 West 57th Street, Suite 400, New York, NY, operates primarily in the immunotherapy sector with a subsidiary in Tel Aviv, Israel, and focuses on therapeutic areas encompassing blood cancers, hematologic conditions, solid organ transplantation, and autoimmune disorders. In December 2024, Cell Source presented preclinical data on its off-the-shelf Veto CAR-T cell therapy at the American Society of Hematology Annual Meeting, highlighting potential breakthroughs in immune tolerance for next-generation cancer treatments. Earlier milestones include a 2014 acquisition of Cell Source (Israel) Ltd. and $3.6 million private placement to fund clinical advancement, alongside a 2015 convertible note financing of $3 million.
Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week
Cell Source, Inc. to Present at the LD Micro Invitational XVI
Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent